Abstract: The present disclosure is directed to injectable formulations that include biodegradable polymers based on trimethylene carbonate (TMC) with mole fractions of polylactic acid (PLA) and/or polyglycolic acid (PGA) that are used to deliver a bioactive agent to a targeted site. Excipients such as polyethylene glycol (PEG) may be added to the formulations to reduce the injection force and/or to modulate the release of the bioactive agent. Suitable biodegradable polymers for use in the injectable formulations include D,L-PLA:TMC, D-PLA:TMC, L-PLA:TMC, TMC:PLA:PGA and variations thereof. Additionally, copolymers of TMC and PLA and terpolymers of TMC:PLA:PGA may be formed into nanoparticles and delivered to the target site with an injectable crosslinkable polyethylene glycol system. In at least one embodiment, the injectable formulations are used to treat ocular diseases.

Abstract: The present disclosure is directed to injectable formulations that include biodegradable polymers based on trimethylene carbonate (TMC) with mole fractions of polylactic acid (PLA) and/or polyglycolic acid (PGA) that are used to deliver a bioactive agent to a targeted site. Excipients such as polyethylene glycol (PEG) may be added to the formulations to reduce the injection force and/or to modulate the release of the bioactive agent. Suitable biodegradable polymers for use in the injectable formulations include D,L-PLA:TMC, D-PLA:TMC, L-PLA:TMC, TMC:PLA:PGA and variations thereof. Additionally, copolymers of TMC and PLA and terpolymers of TMC:PLA:PGA may be formed into nanoparticles and delivered to the target site with an injectable crosslinkable polyethylene glycol system. In at least one embodiment, the injectable formulations are used to treat ocular diseases.

Abstract: Bioabsorbable self-expanding medical devices formed of an integral framework with a multiplicity of fenestrations are provided. The framework is continuous, non-filamentous, non-braided, and non-interlaced. The devices includes a non-blended hydrolysable co-polymeric material comprising an amorphous component with a glass transition temperature that is below ambient body temperature and a crystallizable component that possesses a crystalline melting point in excess of ambient body temperature. The devices radially expand from a compressed first diameter to an uncompressed second diameter equal to or greater than 1.5 times the first diameter within two minutes in an aqueous medium at 37° C. following release of a compressive force placed on the devices. Additionally, the medical device does not change axial length significantly as the radial dimensions of the devices are changed.

Abstract: The present invention is directed to bioabsorbable self-expanding medical devices for use inside or outside body conduits that self-expand at, or below, normal human body temperature without requisite for a polymeric thermal transition.

Abstract: A percutaneous device to provide a path from the exterior of the epidermal tissue to interior body spaces and structures with a skirt of material with PTFE having an open microstructure for the ingrowth of epidermal and connective tissue.